CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced robust lobe-specific changes in white ...

Researchers analyzed longitudinal changes in substructure brain volumes after menopause in women with multiple sclerosis.

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and ...

The structural and functional organization of the brain as shown on MRI can predict the progression of brain atrophy in patients with early-stage, mild Parkinson's disease, according to a study ...

A long-term brain imaging study in aging adults showed faster rates of atrophy in certain brain structures to be associated with the risk of developing mild cognitive impairment (MCI). While some ...

A new brain imaging study provides evidence that high levels of iron in certain parts of the brain may signal an increased ...

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...

Anti-amyloid-beta (anti-Aβ) drugs, which are used in the management of Alzheimer's disease (AD), have the potential to compromise long-term brain health by accelerating brain atrophy, a comprehensive ...

An enlargement of the brain ventricle might set off alarm bells in a neurologist's office. And yet, in people on anti-amyloid immunotherapy, it occurs quite commonly. Is this a red flag, or an ...